Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT…
ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)
Recover your password.
A password will be e-mailed to you.